-+ 0.00%
-+ 0.00%
-+ 0.00%

Cybin’s Helus Pharma closes US$50 million follow-on common share offering at US$4.85/share

PUBT·06/25/2026 13:30:52
Listen to the news
Cybin’s Helus Pharma closes US$50 million follow-on common share offering at US$4.85/share
  • Cybin’s Helus Pharma unit closed a US$50 million underwritten follow-on equity offering of 10,309,280 common shares at US$4.85 each.
  • Cantor Fitzgerald, Barclays led the deal; Bloom Burton Securities, Lucid Capital Markets served as lead managers.
  • Net proceeds earmarked for HLP003 Phase 3 program in major depressive disorder, HLP004 in generalized anxiety disorder, other pipeline work.
  • Cash underwriting commission totaled US$3 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.